Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer DrugsInvestors Business Daily • 11/07/23
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI CancersBusiness Wire • 11/06/23
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI CancersBusiness Wire • 11/06/23
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & MoreZacks Investment Research • 11/06/23
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023Business Wire • 11/03/23
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023Business Wire • 11/02/23
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDSBusiness Wire • 10/24/23
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIVBusiness Wire • 10/20/23
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of ComorbiditiesBusiness Wire • 10/19/23
Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead StockInvestors Business Daily • 10/18/23
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose ProgramBusiness Wire • 10/18/23
Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugsMarket Watch • 10/17/23
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral DiseasesBusiness Wire • 10/17/23
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023Business Wire • 10/16/23